Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Full Text
Share
The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve this conundrum and beneficially impact the state of cancer-immune system interactions
This document is licensed under a Creative Commons:Attribution - Non commercial - No Derivate Works (by-nc-nd)

Related items
Showing items related by title, author, creator and subject.